Oral *Escherichia coli* expressing IL-35 meliorates experimental colitis in mice

Baoren Zhang¹,²†, Yi Liu³†, Xu Lan¹,², Xiaoxi Xu⁴, Xiaoning Zhang³, Xiang Li¹,², Yiming Zhao¹,², Guang Li³, Caigan Du⁵,⁶, Shanzheng Lu⁷ and Hao Wang¹,²*

**Abstract**

**Background:** Ulcerative colitis (UC) is a subtype of inflammatory bowel disease (IBD) characterized by chronic inflammation of colon. It is commonly believed that the imbalance of immune system and overwhelming production of cytokines are involved in the pathogenesis of UC. Recent studies demonstrated that interleukin-35 (IL-35), a key player in the regulation of inflammation, has been identified as potential therapeutic target to treat UC. However, conventional intravenous administration is costly and inconvenient. The present study was designed to establish a novel IL-35 delivery system and investigate its therapeutic effects on dextran sulfate sodium (DSS)-induced experimental colitis in mice for the first time.

**Methods:** An engineered *Escherichia coli* (*E. coli/IL-35*) expressing IL-35 was constructed. Adult male BALB/c mice randomly got the oral administration of *E. coli/IL-35*, empty plasmid-transformed *E. coli* (*E. coli0*) or PBS for treatment following ingestion of 3% DSS solution for 5 days. Normal mice were used as control group. Colonic and splenic tissues were collected on day 10 post-DSS-induction. Clinical signs, disease activity index (DAI), pathological and immunohistological changes, cytokine profiles and cell populations were evaluated.

**Results:** Intragastric administration of *E. coli/IL-35* effectively protected the colitis mice from DSS assimilation including weight loss and colon shortening. Pathological analysis showed significantly lower DAI score and much less intra-colon infiltration of neutrophils and CD3⁺ cells in the IL-35 treated group. Moreover, *E. coli/IL-35*-treated mice demonstrated much less CD4⁺ IL-17A⁺ Th17 cells and a higher level of CD4⁺CD25⁺Foxp3⁺ Tregs in spleen and mesenteric lymph nodes, as well as increased colon and serum level of IL-10 and IL-35 and decreased levels of IL-6.

**Conclusions:** Our study showed that *E. coli/IL-35* as a novel oral IL-35 delivery system alleviated inflammatory damage of colonic tissue in the colitic mice. Genetic therapeutic strategies using engineered *E. coli* encoding immunoregulatory cytokines may provide a potential approach for the treatment of IBD.

**Keywords:** Colitis, IL-35, Mice, *Escherichia coli*, Anti-inflammatory

**Background**

Ulcerative colitis (UC) is a subtype of inflammatory bowel disease (IBD), characterized by chronic inflammation of the bowel with periods of exacerbation and remission of abdominal pain, diarrhea, purulent stools and relapses [1]. UC is a public problem among individuals of European descent living in wealthy Western countries, while, recent population-based and referral center cohorts have shown a rising incidence and prevalence in Asia [2, 3]. UC featured by ulceration and inflammation in the mucosa and submucosa of the large intestine is considered to be related with overly aggressive T cell-mediated immune responses to intestinal microbiota components in genetically susceptible hosts, with disease initiated and reactivated by environmental triggers [4, 5]. Currently, the pharmaceutical treatments for UC include glucocorticosteroids, immunosuppressive agents and emerging biologic therapy (anti-TNF-α monoclonal antibody). However, there remains a significant cohort of
patients with refractory or relapsing disease those who cannot tolerate currently available medical therapy. Also, existing therapeutic options carry an increased risk of infective and malignant diseases [6].

Cytokines, soluble mediators of the inflammatory response secreted by a myriad of cells, take part in the immune reaction. Interleukins are key constituents of the cytokine profile found in the intestinal mucosa of IBD patients and thus have been identified as potential future therapeutic targets [7]. IL-35, composed by heterodimerization of 2 subunits Epstein–Barr virus-induced gene 3 (EBI3) and the IL-12 p35 subunit (IL-12A), has immunosuppressive effects mediated through regulatory T (Tregs) and B cells [8]. Recent studies also demonstrated the anti-inflammatory properties of IL-35 in facilitating the suppressive Treg cells [8, 9], and restricting inflammatory Th17 cells [10–12], making it a promising candidate for treating UC. However, systemic administration of such molecules has several drawbacks including short bioactivity, systemic toxicity, and high cost. Thus, searching for a more effective and economic therapeutic strategy is warranted.

Treatment through regulating intestinal flora attracted much attention in recent years. Traditional probiotics showed limited effectiveness in the treatment of UC, whereas E. coli Nissle maintains remission and possibly reduce active inflammation [13]. As the proximal colon exposes to luminal bacteria, colonic mucosa delivery of IL-35 was achieved by oral administration of an invasive and non-pathogenic E. coli. In the current study, we constructed a vector of pET-28a(+)–IL35 and used it to design an recombinant E. coli (E. coli/IL-35), aimed to provide therapeutic levels of IL-35 directly in the colon.

**Methods**

**Construction of recombinant IL-35 expressing E. coli/IL-35**

pET-28a(+) vector was obtained from Cwbiotech, China. The sequence of IL-35 was a generous gift from Prof. Jiuyu Ju (Weifang Medical University, Shandong). The IL-35 segment was gained using EcoI/XhoI double digestion and subcloned into pET-28a(+) vector linearized to construct pET-28a(+)–IL35 recombinant plasmid, which was transformed into E. coli strain BL21(DE3) to get E. coli/IL-35. The same strain carrying empty-load vector (pET-28a(+)) was used as E. coli/0. The expression of the exogenous protein was induced by the addition of 1 mM Isopropyl-β-d-thiogalactopyranoside (IPTG) for 4 h at 37 °C post cultured overnight in LB-medium. Then cells were harvested by centrifugation at 7000×g for 10 min at 4 °C, and the obtained pellets were assessed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting to confirm the expression of IL-35 by anti-IL-12A (Abcam, China).

**Animals**

The entire experiment was approved by the Animal Care and Use Committee of Tianjin Medical University (China) according to the Chinese Council on Animal Care guidelines. The male SPF BALB/c mice (Aoyide Co., Tianjin, China) aged 6–8 weeks and weighing 18 ± 2 g. They were housed in comfortable cages at Animal Care Facility of Tianjin General Surgery Institute and allowed to acclimatize to standard lighting, and temperature conditions with food and water freely available before the experiment were performed.

**Experimental groups**

The mice were randomly divided into four groups (n = 10 mice per group) as follows: normal group, DSS group, DSS + E. coli0 group, DSS + E. coli/IL-35 group. DSS-induced colitis model was established in mice according to Kihara et al. [14]. Colitis was induced in 30 mice by free access to 3% DSS solution for 5 days followed by additional 5 days with drinking water without DSS. Mice in DSS group were given 0.2 mL PBS once a day through an oral-gastric tube during the last 5 days. In the DSS + E. coli/IL-35 group, mice were treated with 0.2 mL of PBS suspensions (1 × 1010 CFU/mouse/day) of E. coli/IL-35 induced with 1 mM IPTG for 4 h, while those were given the same amount of PBS containing E. coli0 as control in DSS + E. coli0 group. All mice were sacrificed by cervical dislocation and examined as described below after fast for 6 h.

**Assessment of inflammation severity**

The degree of inflammation in mice was comprehensively assessed by daily disease activity index (DAI) and length of the colon. Briefly, DAI was adopted based on the scoring system of Murthy et al. [15], which represents the sum of scores for weight loss, stool consistency and rectal bleeding divided by three. The colon (from the ileocecal junction to the anus) was collected and the length of it was measured. Then the colon was cut longitudinally and washed by cold saline, and the colonic contents were removed.

**Histological evaluation**

Colon samples were cleaned with saline, fixed in 10% neutral buffered formalin, embedded in paraffin and cut into 5 μm sections. Specimens were dewaxed, hydrated and stained with standard hematoxylin and eosin (H&E) to examine pathological changes in a blinded fashion. The colitis score was used to determine the extent of the inflammation based on a previously published grading system [16], which according to the criteria (a) inflammation severity: 0 (none), 1 (slight), 2 (moderate), 3 (severe);
with 3% H2O2 followed by deparaffination and rehydration.

Endogenous peroxides of colon specimens were blocked
antibodies were calculated. In addition, the population of intracellular IL-17A+ cells were calculated. And for the Th17 cells, the population of intracellular IL-17A+ cells stained with anti-mouse IL-17A antibody were calculated.

The transcriptional gene levels of IL-6, IL-10, IL-35 and IL-12 in colon tissues were determined by quantitative real-time PCR instrument. Total RNA was extracted from colon tissue using TRIzol reagent, and two μg RNA was reverse transcribed into cDNA with the QuantiTect Reverse Transcription Kit (Qiagen) using random hexamers. Quantitative real-time PCR was conducted using the TaqMan gene expression assay with a LightCycler 1.5. GAPDH served as an internal control. The sequences of primers used for analysis were designed as follows: GAPDH, sense 5'-AGGTCGGTGAAACGGATTTG-3', antisense 5'-TGTTAGACCATGTAGTTGGTCA-3'; IL-12a, sense 5'-GACCTGGACCCCTAGATTGAA-3', antisense 5'-GGTCTCTTGAGCCAGCTTTA-3'; IL-10, sense 5'-AGAAGCATGGCCCAAGAATCA-3', antisense 5'-GGCTTTGTAGACACCTTGT-3'; IL-6, sense 5'-CCACTTCAAAGTGGGACCTA-3', antisense 5'-GCAAGTGTCACTGCTTGTAC-3'; EBI3, 5'-GTTTCACAGGAGGCTCTA-3', antisense 5'-CCGTTTGATTGCCCTAC-3'; IL-12p40, sense 5'-CTTGGACCGACAGGATGTGAGT-3', antisense 5'-CTTGGACCGACAGGATGTGAGT-3'.

Enzyme-linked immunosorbent assay (ELISA)
Serum was prepared and subjected to ELISA to determine levels of IL-10, IL-35 and IL-6 using ELISA kits (Biolgend, http://www.biolegend.com/) according to the protocol provided by the manufacturer. ELISA was performed in triplicate for each sample.

Statistical analysis
SPSS 17.0 (SPSS Inc., Chicago, USA) was used for the statistical analysis. The enumeration data were performed as mean±standard deviation (SD). One-way ANOVA was used for multiple-group comparisons and with proper post hoc analysis. A significant difference was defined as p<0.05.

Results
Construction of pET28a(+)–IL-35 and detection of IL-35 expression in E. coli/IL-35 in vitro and vivo
The pET28a(+)–IL-35 recombinant plasmid was identified by PCR, EcoR I/Xhol double enzyme digestion and nucleotide sequencing (Fig. 1a, b). The IL-35 expression was analyzed using SDS-PAGE after IPTG treatment. As shown in Fig. 1c, a prominent band of about 56 kDa in the bacteria was transformed with pET-28a(+)–IL-35. This band matched the theoretical molecular weight of IL-35 and it was not present in the E. coli/0. Consistently, western blot exhibited a strong protein band of 56 kDa in the cell lysate of E. coli/IL-35 instead of E. coli/0 post induction in Fig. 1d, indicating the successful and stable expression of IL-35. As shown in Fig. 1e, f, after administration of bacterial, the mRNA levels of IL-12A, EBI3 and the serum concentration of IL-35 were significantly
increased in the DSS + E. coli/IL-35 group compared to that of in the DSS and DSS + E. coli/0 groups (*p < 0.05).

Administration of E. coli expressing IL-35 ameliorates symptoms of DSS-induced colitis
DAI score has long been used for evaluating the colon injury. Following induction with DSS, all mice exhibited colitis with persistent liquid or bloody stool, weight loss, and lethargy in all groups before E. coli administration. After bacterial treatment, mice in DSS + E. coli/IL-35 group showed significantly less body weight loss (*p < 0.05) (Fig. 2a), firmer stool, as well as food and water consumption with much lower DAI score (*p < 0.05) (Fig. 2b) compared to those in DSS and DSS + E. coli/0 group. Besides, mice exposed to DSS demonstrated severe intestine shortening and bowel dilation due to intestinal inflammation compared to normal mice. In the DSS + E. coli/IL-35 Group, obvious bowel dilation was not observed, and the length of the colon was significantly longer than that of DSS and DSS + E. coli/0 group (*p < 0.05) (Fig. 2c). Microscopically, DSS intake caused epithelial injury, while in DSS + E. coli/IL-35 Group, mouse colon presented an improved structure of epithelium and crypts, with much less inflammatory cell infiltration but more regenerative goblet cells. Also, the histopathological scores in DSS + E. coli/IL-35 group were significantly lower than that of DSS and DSS + E. coli/0 groups (*p < 0.05) (Fig. 2d), suggesting the greatly alleviated injury in the colon following E. coli/IL-35 treatment.

E. coli/IL-35 suppressed intra-colon infiltration of neutrophils and T cells in the colitis mice
To investigate the effects of E. coli/IL-35 on attenuation of inflammatory cell infiltration in the colitic mice, we detected and compared intra-colon neutrophil cell and CD3+ cell infiltration in all groups. As shown in Fig. 3, neutrophil cell and CD3+ cell infiltrations were markedly increased in DSS and DSS + E. coli/0 groups compared with those of normal group and DSS + E. coli/IL-35 group (*p < 0.05) (Fig. 3a), which demonstrated that administration of E. coli/IL-35 effectively suppressed neutrophil cell and CD3+ cell infiltration.

Effects of E. coli/IL-35 on spleen and MLN Tregs/Th17 balance
The effect on Treg/Th17 ratio of IL-35 has been reported, and we also tested the Tregs/Th17 balance in mice spleen and MLN using flow cytometry. As shown in Fig. 4, the
**Figure 1:**

**a)** Graph showing Body weight (%) over time for different groups:
- Normal
- DSS
- DSS+E.coli/0
- DSS+E.coli/IL-35

**b)** Graph showing DAL for different groups:
- Normal
- DSS
- DSS+E.coli/0
- DSS+E.coli/IL-35

**c)** Images of colon morphology:
- Normal group
- DSS group
- DSS+E.coli/0 group
- DSS+E.coli/IL-35 group

**d)** Images of histopathological scores:
- Normal group
- DSS group
- DSS+E.coli/0 group
- DSS+E.coli/IL-35 group
levels of CD4⁺CD25⁺Foxp3⁺ Tregs in spleen (Fig. 4a) and MLN (Fig. 4b) were lower in DSS-ingested mice than normal, while the levels of CD4⁺IL-17A⁺ Th17 cells were much higher. Treatment with E. coli/IL-35 significantly enhanced the percentage of Tregs but reduced that of Th17, indicating that E. coli/IL-35 improved the Tregs/Th17 ratio in spleen and MLN.

Transcription Level of IL-6, IL-10, IL-35 and IL-12 in colon tissues
To determine whether bacterial treatment would affect the transcriptional levels of cytokines, we measured the intra-colon expression of IL-6, IL-10 and IL-12p40 by real-time PCR. As shown in Fig. 5, after administration of bacterial, the mRNA levels of IL-10 were significantly increased in the DSS+E. coli/IL-35 group compared to that of in the DSS and DSS+E. coli/0 groups (*p < 0.01) (Fig. 5a). While, no difference between DSS and DSS+E. coli/0 groups could be observed. DSS ingestion significantly increased the IL-6 level in colitis mice. However, the increase in IL-6 got effectively attenuated in the DSS+E. coli/IL-35 group (*p<0.01) (Fig. 5b). IL-12p40 level was also detected to exclude the therapeutic potential of IL-12, and the result showed that DSS intake remarkably reduce IL-12p40 expression and E. coli/IL-35 treatment did not change the tendency (*p<0.01) (Fig. 5c), indicating that IL-35 overexpression contributed more to the benefits post E. coli/IL-35 administration rather than IL-12.

Effect of E. coli/IL-35 on mouse serum cytokine level
To determine whether E. coli/IL-35 treatment could affect cytokine profiles, the levels of systemic inflammatory cytokines were analyzed and compared among different groups. The serum concentration of antiinflammatory cytokine IL-10 (Fig. 6) were notably elevated post-E. coli/IL-35 treatment. Also, the level of pro-inflammatory cytokine (IL-6) was markedly increased in DSS and DSS+E. coli/0 groups, which got significantly reduced in E. coli/IL-35 group (Fig. 6). Taken together, treatment with E. coli/IL-35 not only suppress the level of pro-inflammatory cytokines, but also enhance the level of an anti-inflammatory cytokine in colitis mice.

Discussion
In the present study, we investigated the therapeutic effects of oral administration of E. coli/IL-35 on DSS-induced experimental colitis in a mouse model. E. coli/IL-35 treatment significantly decreased DAI, attenuated body weight loss, with less intestinal shortening and histopathological changes. Meanwhile, upon treatment with E. coli/IL-35, the proportion of Tregs increased, and Th17 cells decreased both in spleen and MLN compared with that of DSS group or DSS+E. coli/0 group, which was also reflected by the correction of cytokine levels in colon tissues. Taken together, these data provided strong evidence that the E. coli/IL-35 treatment significantly affected not only intestinal but also systemic immune responses in UC mice.

UC characterized by chronic and nonspecific inflammation in the large intestine, has been a public problem in western societies. Existing treatments include anti-inflammation drugs and immunosuppressive drugs, which exert a total immunosuppression risk. Recently, analysis of immunoinflammatory pathways in the gut of UC patients has shown that tissue damage is driven by a complex and dynamic crosstalk between immune and nonimmune cells, where cytokines are key mediators of this interplay [18]. The agents targeting tumor necrosis factor (TNF) have been widely acknowledged as the preferred drug in moderating severe UC and CD for more...
than 15 years [19]. However, systemic distribution to all tissues confers risk of several adverse events, such as infection, lupus-like autoimmunity reactions, and hypersensitivity reactions. Thus, a novel delivery method targeting colon with fewer side effects and higher local drug concentration is needed [7]. Recent studies suggest that engineered intestinal flora can be used as an ideal candidate for local drug delivery.

The bacterial community consists of a complex of microorganism species. *Escherichia coli* is the predominant facultatively anaerobic Gram-negative bacterial species of the normal intestinal flora, in which it plays important roles in promoting the stability of the luminal microbial flora and maintaining normal intestinal homeostasis [20]. Here, a noninvasive *E. coli* BL21 (DE3) expressing a potent anti-inflammatory peptide IL-35 was utilized to provide therapeutic level produced directly in the colon, which was the first use of IL-35 engineered bacteria in colitis treatment. We found a noticeable increase of the cytokine IL-35 among colon
specimens in DSS + E. coli/IL-35 group post oral administration (Fig. 1f). Meanwhile, mice treated with E. coli/IL-35 showed significantly reduced weight loss, colon shortening as well as much lower DAI and histological changes (*p < 0.05) (Fig. 2b, d), indicating the effective protection of colon from DSS damage.

Neutrophils and CD3⁺ cell are accumulated in inflamed mucosa of IBD and play an essential role in the pathogenesis [21]. Neutrophils have been found to produce several so-called resolution factors such as lipids mediators [22]. In IBD the tissue damage induced by neutrophils seems higher than normal because of impaired apoptosis and phagocytosis of neutrophils followed by a subsequently extended lifespan [23]. Our study demonstrated that E. coli/IL-35 could remarkably reduce the numbers of Ly6G-positive cells and CD3⁺ cell in the colon compared to that of the untreated group (Fig. 3). Therefore, the beneficial effect on colon exposed to DSS of IL-35 treatment could partly attribute to its suppression of inflammatory cell infiltration.

Much evidence suggests that UC is closely related to the imbalance of Treg/Th17 [24–27]. Tregs mainly function in the suppression of immune responses and maintenance of peripheral tolerance and IBD patients exert lower Tregs level compared to healthy individuals. Th17 cells massively infiltrate the inflamed intestine of IBD patients, where they produce IL-17A and other cytokines, triggering and amplifying the inflammatory process [28]. Thus, Tregs upregulation and/or Th17 suppression may provide a positive intervention...
on UC or IBD. IL-35 plays an essential role in promoting the optimally suppressive function of Treg cells in vitro and controlling homeostatic proliferation in vivo [9]. Some reports implied that IL-35 could suppress differentiation and function of Th17, rather than TGF-β or IL-10 [10–12]. Systemic delivery of an IL-35 adenoviral vector inhibited disease activity in both DSS and TNBS colitis models [12]. Therefore, bolstering IL-35 induced anti-inflammatory action for therapeutic benefit may be a promising strategy in IBD therapy. We detected the Tregs and Th17 cells of mice splenic and MLN and the results demonstrated that *E. coli*/IL-35 treatment significantly increased the level of CD4^+CD25^+Foxp3^+ Tregs in spleen and MLN compared to that of *E. coli*/0 and PBS group, while the CD4^+IL-17A^+ Th17 level got suppressed efficiently (*p < 0.05) (Fig. 4). Interleukins are critical constituents of the cytokine profile participating in intestinal inflammation of IBD patients. The serum and colon levels of pro-inflammatory cytokine IL-6 and anti-inflammatory cytokine IL-10 were measured by Elisa and real-time PCR respectively. The data showed that *E. coli*/IL-35 administration dramatically reduced the serum IL-6 concentration and increased the IL-10 level, compared to those of untreated mice (*p < 0.05) (Fig. 6). Transcription level analysis of IL-10 and IL-6 in colon tissue got a similar result (Fig. 5a, b). IL-6 has been considered as an essential cytokine for Th17 differentiation, and the lower Th17 cells in *E. coli*/IL-35 treated mice might be partly related to IL-6 reduction. IL-10 is a well-known tolerogenic cytokine, whose capacity to relieve the intestinal inflammation in UC has been verified [29]. Also, there are reports stated that IL-35 could promote IL-10 secretion and we indeed observed the same result post *E. coli*/IL-35 treatment. These findings implied that local administration of IL-35 by recombinant *E. coli* effectively intervened in the pathological inflammation caused by DSS exposure and the positive effect was partly due to the immune homeostasis improvement in the colon and whole body.

**Conclusion**

The present study tested the efficacy of recombinant bacteria *E. coli*/IL-35 in the colitis mice post oral administration. The data indicated that *E. coli*/IL-35 treatment significantly affected not only intestinal but also systemic immune responses in UC mice. In conclusion, *E. coli*, as a novel delivery system to deliver IL-35, provides an alternative strategy for DSS-induced ulcerative colitis therapy. However, further studies are still needed to elucidate the complex pathways underlying *E. coli*/IL-35-mediated colon protective effects.

**Abbreviations**

UC: ulcerative colitis; IBD: inflammatory bowel disease; IL: interleukin; DSS: dextran sulfate sodium; *E. coli*: *Escherichia coli*; EBI3: Epstein–Barr virus-induced gene; IPTG: isopropyl-β-d-thiogalactopyranoside; DAI: daily disease activity index; Ly6G: lymphocyte antigen 6 complex, locusG; MLN: mesenteric lymph nodes; Treg: regulatory T cell; TNF: tumor necrosis factor; TGF-β1: transforming growth factor-β1.

**Authors’ contributions**

BZ and YL: conception and design, performance of the research, data analysis and interpretation and manuscript writing. XL, XX and XZ: performance of the research, data analysis and interpretation. GL and CD: data analysis and interpretation, manuscript writing. SL: performance of the research. HW: conception and design, financial support, administrative support, manuscript writing. All authors read and approved the final manuscript.
Author details
1 Department of General Surgery, Tianjin Medical University General Hospital, 154 Anshan Road, Heping District, Tianjin 300052, China. 2 Tianjin General Surgery Institute, Tianjin, China. 3 Department of Genetics, College of Basic Medical Sciences, Tianjin Medical University, Tianjin, China. 4 Department of Endocrinology, Tianjin Medical University General Hospital, Tianjin, China. 5 Department of Urologic Sciences, The University of British Columbia, Vancouver, BC, Canada. 6 Immunity and Infection Research Centre, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada. 7 Department of Anorectal Surgery, People’s Hospital of Hunan Province, First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China.

Acknowledgements
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
Materials used for the current study are available from the corresponding author on reasonable request.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Ethics approval and consent to participate not applicable for patients. The entire experiment was approved by the Animal Care and Use Committee of Tianjin Medical University (China) according to the Chinese Council on Animal Care guidelines.

Funding
This work was supported by Grants to H.W. from National Natural Science Foundation of China (Nos. 81273257 and 81471584), Tianjin Application Basic Foundation of China (Nos. 13JCQNJC08700), Li Jeshou Intestinal Barrier Research Special Fund (No. LJS_201412), and Tianjin Medical University Talent Fund, and to Y.L. from National Natural Science Foundation of China for Young Scholars (No. 81501386).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 8 November 2017 Accepted: 5 March 2018

Published online: 20 March 2018

References
1. Knigge KL. Inflammatory bowel disease. Clin Cornerstone. 2002;4(4):49–60.
2. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Femia M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time: based on systematic review. Gastroenterology. 2012;142(1):46–54.
3. Ng SC, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, Wong TC, Leung VK, Tsang SW, Yu HH, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Cronh’s and colitis epidemiology study. Gastroenterology. 2013;145(1):158–65.
4. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146(6):1489–99.
5. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134(2):577–94.
6. Ahluwalia JP. Immunotherapy in inflammatory bowel disease. Med Clin North Am. 2012;96(3):525–44.
7. McLean MH, Neurath MF, Durum SK. Targeting interleukins for the treat-
ment of inflammatory bowel disease—what lies beyond anti-TNF therapy? Inflamm Bowel Dis. 2014;20(2):389–97.
8. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Seyh D, Blumberg RS, Vignali DA. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450(7169):566–9.
9. Collison LW, Chatuvedi V, Henderson AL, Giacomini PR, Guy C, Bankoti J, Finkenstein D, Forbes K, Workman CJ, Brown SA, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010;11(12):1093–101.
10. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McNlnes IB, Liev FY. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol. 2007;37(1):3021–9.
11. Whitehead GS, Wilson RH, Nakano K, Burch LH, Nakano H, Cook DN. IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. J Allergy Clin Immunol. 2012;129(1):207–15.
12. Wirtz S, Billmeier U, McHedlidze T, Blumberg RS, Neurath MF. Interleu-
kin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology. 2011;141(5):1875–86.
13. Sartor RB, Wu GD. Roles for intestinal bacteria, viruses, and fungi in patho-
genesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology. 2017;152(2):327–39.
14. Khara N, de la Fuente SG, Fujikyo K, Takashashi T, Pappas TN, Mantyry CR. Vanillilod receptor-1 containing primary sensory neurones mediate dextran sulphate sodium induced colitis in rats. Gut. 2003;52(5):713–9.
15. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicoopathologic study of dextran sulphate sodium experimental murine colitis. Lab Invest. 1993;69(2):238–49.
16. Mantyry CR, Pappas TN, Lapp JA, Washington MK, Neville LM, Ghiolardi JR, Rodgers SD, Mantyry PW, Vigna SR. Substance P activation of enteric neu-
rons in response to intraluminal Clostridium difficile toxin A in the rat ileum. Gastroenterology. 1996;111(5):1272–80.
17. Lv Y, Xu X, Zhang B, Zhou G, Li H, Du C, Han H, Wang H. Endometrial regenerative cells as a novel cell therapy attenuate experimental colitis in mice. J Transl Med. 2014;12:344.
18. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflam-
matory bowel disease. Nature. 2011;474(7351):298–306.
19. Cohen BL, Sachar DB. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017;357:j2505.
20. Darfeuille-Michaud A, Colombel JF. Pathogenic Escherichia coli in inflam-
matory bowel disease proceedings of the 1st international meeting on E. coli and IBD, June 2007, Lille, France. J Crohns Colitis. 2008;2(3):255–62.
21. Zhou G, Yu L, Fang L, Yang W, Yu T, Mao Y, Chen M, Wu K, Chen F, Cong Y, et al. CD177+ neutrophils as functionally activated neutrophils negatively regulate IBD. Gut. 2017. https://doi.org/10.1136/gutjnl-2016-313535.
22. Rogler G. Resolution of inflammation in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2017;2(7):521–30.
23. Fournier BM, Parkos CA. The role of neutrophils during intestinal inflam-
mation. Mucosal Immunol. 2012;5(4):354–66.
24. Hundorf G, Neurath MF, Muderer J. Functional relevance of T helper 17
(Th17) cells and the IL-17 cytokine family in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(1):180–6.
25. Oginho Jr, Nakamura K, Ibara E, Akiko H, Takayamaan R. CD4+CD25+ regula-
tory T cells suppress Th17-responses in an experimental colitis model. Dig Dis Sci. 2011;56(2):376–86.
26. Zhang L, Zhang Y, Dong L, Li C, Lin X, Xia Z. Heme oxygenase-1 amelio-
rates dextran sulphate sodium-induced acute murine colitis by regulating Th17/Treg cell balance. J Biol Chem. 2014;289(39):26847–58.
27. Zhang M, Zhou Q, Dorfman RG, Huang X, Fan T, Zhang H, Zhang J, Yu C. Butyrate inhibits interleukin-17 and generates Tregs to ameliorate colorectal colitis in rats. BMC Gastroenterol. 2016;16(1):84.
28. Galvez J. Role of Th17 cells in the pathogenesis of human IBD. ISRN Inflamm. 2014;2014:928461.
29. Szkardaikiewicz A, Marciniak R, Chudzicka-Strugala I, Wasilewska A, Drews M, Majewski P, Karpinski T, Zwodzick B. Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients. Arch Immunol Ther Exp (Warsz). 2009;57(4):291–4.